{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T03:30:16Z","timestamp":1764905416017},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2011,3,26]],"date-time":"2011-03-26T00:00:00Z","timestamp":1301097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Janssen Pharmaceutical Companies of Johnson & Johnson in Europe"},{"name":"Middle East, and Africa"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices.<\/jats:p>","DOI":"10.1634\/theoncologist.2010-0386","type":"journal-article","created":{"date-parts":[[2011,3,27]],"date-time":"2011-03-27T00:45:39Z","timestamp":1301186739000},"page":"388-403","source":"Crossref","is-referenced-by-count":26,"title":["Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective"],"prefix":"10.1093","volume":"16","author":[{"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[{"name":"a Wilhelminenspital, Vienna, Austria;"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[{"name":"b Ankara University, Department of Haematology, Ankara, Turkey;"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[{"name":"c Department of Hematology, Hospital Clinic, Barcelona, Spain;"}]},{"given":"Jamie","family":"Cavenagh","sequence":"additional","affiliation":[{"name":"d Department of Haematology, St Bartholomew's Hospital, London, United Kingdom;"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"e Institute of Hematology and Medical Oncology, Seragnoli, Bologna, Italy;"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[{"name":"f Department of Hematology, University Hospital Leuven, Leuven, Belgium;"}]},{"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"g Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece;"}]},{"given":"Johannes","family":"Drach","sequence":"additional","affiliation":[{"name":"h Department of Oncology, University Clinic Vienna, Vienna, Austria;"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"i Universit\u00e4tsklinik W\u00fcrzburg, Medizinische Klinik und Poliklinik II, W\u00fcrzburg, Germany;"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"j Service d'H\u00e9matologie, Centre Hospitalier Universitaire (CHU), Lille, France;"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"k Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany;"}]},{"given":"Jean-Luc","family":"Harousseau","sequence":"additional","affiliation":[{"name":"l Centre Ren\u00e9 Gauducheau Nantes, Nantes, France;"}]},{"given":"Urs","family":"Hess","sequence":"additional","affiliation":[{"name":"m Division of Oncology\/Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland;"}]},{"given":"Martin","family":"Kropff","sequence":"additional","affiliation":[{"name":"n Department of Medicine\/Hematology and Oncology, University of M\u00fcnster, M\u00fcnster, Germany;"}]},{"given":"Fernando","family":"Leal da Costa","sequence":"additional","affiliation":[{"name":"o Portuguese Institute of Oncology, Lisbon, Portugal;"}]},{"given":"Vernon","family":"Louw","sequence":"additional","affiliation":[{"name":"p Division Clinical Haematology, Department of Internal Medicine, University of the Free State, Bloemfontein, South Africa;"}]},{"given":"Hila","family":"Magen-Nativ","sequence":"additional","affiliation":[{"name":"q Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah-Tiqva, Israel;"}]},{"given":"Larisa","family":"Mendeleeva","sequence":"additional","affiliation":[{"name":"r Hematology Scientific Center, Russian Academy of Medical Sciences, Moscow, Russia;"}]},{"given":"Hareth","family":"Nahi","sequence":"additional","affiliation":[{"name":"s Department of Hematology, Karolinska University Hospital, Huddinge, Stockholm, Sweden;"}]},{"given":"Torben","family":"Plesner","sequence":"additional","affiliation":[{"name":"t Department of Haematology, IRS-CSFU, University of Southern Denmark, Vejle Hospital, Vejle, Denmark;"}]},{"given":"Jes\u00fas","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"u Servicio de Hematolog\u00eda, Hospital Universitario de Salamanca, and CIC, IBMCC (USAL-CSIC), Salamanca, Spain;"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"v Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands;"}]},{"given":"Miklos","family":"Udvardy","sequence":"additional","affiliation":[{"name":"w Institute of Medicine, Medical and Health Science Centre, Debrecen, Hungary;"}]},{"given":"Pia","family":"Sondergeld","sequence":"additional","affiliation":[{"name":"x Ammonite Systems Ltd., Faringdon, United Kingdom;"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[{"name":"y Divisione di Ematologia dell'Universit\u00ed di Torino, Azienda Ospedaliera S. Giovanni Battista, Ospedale Molinette, Turin, Italy"}]}],"member":"286","published-online":{"date-parts":[[2011,3,26]]},"reference":[{"key":"2021122303313761100_B1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2009-0203","article-title":"Current multiple myeloma treatment strategies with novel agents: A European perspective","volume":"15","author":"Ludwig","year":"2010","journal-title":"The Oncologist"},{"key":"2021122303313761100_B2","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma","volume":"92","author":"Velde","year":"2007","journal-title":"Haematologica"},{"key":"2021122303313761100_B3","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","article-title":"Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival","volume":"26","author":"Lahuerta","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B4","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"2021122303313761100_B5","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","article-title":"Importance of achieving a complete response in multiple myeloma, and the impact of novel agents","volume":"28","author":"Chanan-Khan","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B6","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1182\/blood.V116.21.3573.3573","article-title":"A phase III study to compare melphalan, prednisone, lenalidomide (MPR) versus melphalan 200 mg\/m2 and autologous transplantation (MEL200) in newly diagnosed multiple myeloma patients [abstract 3573]","volume":"116","author":"Palumbo","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood.V114.22.352.352","article-title":"The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS [abstract 352]","volume":"114","author":"Morgan","year":"2009","journal-title":"Blood"},{"key":"2021122303313761100_B8","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005\u201301 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B9","article-title":"Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005\u201301 trial","author":"Moreau","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B10","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"2021122303313761100_B11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V116.21.40.40","article-title":"HOVON-65\/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM) [abstract 40]","volume":"116","author":"Sonneveld","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B12","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V116.21.1910.1910","article-title":"Analysis of immunophenotypic response (IR) by multiparameter flow cytometry in 516 myeloma patients included in three consecutive Spanish trials [abstract 1910]","volume":"116","author":"Paiva","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B13","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized, controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"2021122303313761100_B14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.V116.21.622.622","article-title":"A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients \u226565 years with newly diagnosed multiple myeloma (NDMM): Continuous use of lenalidomide vs fixed-duration regimens [abstract 622]","volume":"116","author":"Palumbo","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B15","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood-2010-03-275800","article-title":"Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone","volume":"116","author":"Harousseau","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V116.21.620.620","article-title":"Bortezomib, melphalan, prednisone and thalidomide followed by maintenance with bortezomib and thalidomide (VMPT-VT) for initial treatment of elderly multiple myeloma patients: Updated follow-up and impact of prognostic factors [abstract 620]","volume":"116","author":"Palumbo","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B17","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122303313761100_B18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood.V116.21.1949.1949","article-title":"Achievement of complete response is a strong prognostic factor in elderly newly diagnosed myeloma: Retrospective analysis of 1175 patients [abstract 1949]","volume":"116","author":"Gay","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B19","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3324\/haematol.2009.015917","article-title":"Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma","volume":"95","author":"Harousseau","year":"2010","journal-title":"Haematologica"},{"key":"2021122303313761100_B20","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): A randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"2021122303313761100_B21","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122303313761100_B22","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B23","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122303313761100_B25","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 Study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B26","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V114.22.131.131","article-title":"Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa trial) [abstract 131]","volume":"114","author":"Einsele","year":"2009","journal-title":"Blood"},{"issue":"suppl 2","key":"2021122303313761100_B28","first-page":"451","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib plus thalidomide-dexamethasone as induction prior to autologous transplantation in newly diagnosed myeloma [abstract 1097]","volume":"95","author":"Harousseau","year":"2010","journal-title":"Haematologica"},{"issue":"15 suppl","key":"2021122303313761100_B29","first-page":"576s","article-title":"Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007\u201302 study [abstract 8014]","volume":"28","author":"Moreau","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B30","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood.V116.21.307.307","article-title":"A phase III PETHEMA\/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: Superiority of VTD (bortezomib\/thalidomide\/dexamethasone) over TD and VBMCP\/VBAD plus bortezomib [abstract 307]","volume":"116","author":"Rosi\u00f1ol","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B32","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/leu.2010.82","article-title":"Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005\u201301 trial","volume":"24","author":"Moreau","year":"2010","journal-title":"Leukemia"},{"key":"2021122303313761100_B33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood.V114.22.127.127","article-title":"Novel three- and four-drug combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for newly diagnosed multiple myeloma: Encouraging results from the multi-center, randomized, phase 2 EVOLUTION study [abstract 127]","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"2021122303313761100_B34","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/leu.2010.116","article-title":"Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: Phase 1 results from the multicenter EVOLUTION study","volume":"24","author":"Kumar","year":"2010","journal-title":"Leukemia"},{"key":"2021122303313761100_B35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B36","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1182\/blood.V116.21.3049.3049","article-title":"Phase II trial of lenalidomide, bortezomib, and dexamethasone in patients (pts) with relapsed and relapsed\/refractory multiple myeloma (MM): Updated efficacy and safety data after &gt;2 years of follow-up [abstract 3049]","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"suppl 2","key":"2021122303313761100_B37","first-page":"149","article-title":"Phase II study of bortezomib, thalidomide and dexamethasone\/-cyclophosphamide as induction therapy in previously untreated multiple myeloma (MM): Safety and activity including evaluation of MRD [abstract 371]","volume":"95","author":"Ludwig","year":"2010","journal-title":"Haematologica"},{"key":"2021122303313761100_B38","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/blood-2010-01-264333","article-title":"Total Therapy 3 for multiple myeloma: Prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy","volume":"116","author":"Rhee","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B39","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood.V116.21.305.305","article-title":"Bortezomib-based induction therapy followed by autologous stem cell transplantation and maintenance therapy with bortezomib improves outcome in myeloma patients with fain 1q21 and t(4;14)\u2014a subgroup analysis of the HOVON-65\/GMMG-HD4 trial [abstract 305]","volume":"116","author":"Goldschmidt","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B41","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1182\/blood.V116.21.309.309","article-title":"Clinical outcome according to both cytogenetic abnormalities (CA) detected by fluorescence in situ hybridization (FISH) and hyperdiploidy assessed by flow cytometry (FCM) in elderly newly diagnosed myeloma patients treated with a bortezomib-based combination [abstract 309]","volume":"116","author":"Mateos","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B42","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/blood.V116.21.781.781","article-title":"Bortezomib-based induction treatments improve outcomes of newly diagnosed multiple myeloma patients with high-risk cytogenetic abnormalities [abstract 781]","volume":"116","author":"Cavo","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B43","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"2021122303313761100_B44","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","article-title":"Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: A study of the Intergroupe Francophone du My\u00e9lome","volume":"26","author":"Decaux","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B45","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","article-title":"Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients","volume":"116","author":"Broyl","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B46","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-09-2831","article-title":"Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome","volume":"16","author":"Dickens","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122303313761100_B47","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","article-title":"Superior results of Total Therapy 3 (2003\u201333) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006\u201366 with VRD maintenance","volume":"115","author":"Nair","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B48","volume-title":"Study to compare VMP with HDM followed by VRD consolidation and lenalidomide maintenance in patients with newly diagnosed multiple myeloma (HO95)"},{"key":"2021122303313761100_B49","volume-title":"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (IFM\/DFCI2009)"},{"key":"2021122303313761100_B50","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"2021122303313761100_B51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood.V116.21.310.310","article-title":"Maintenance treatment with lenalidomide after transplantation for myeloma: Final analysis of the IFM 2005\u201302 [abstract 310]","volume":"116","author":"Attal","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B52","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood.V114.22.530.530","article-title":"Improved response rate with bortezomib consolidation after high dose melphalan: First results of a Nordic Myeloma Study Group randomized phase III trial [abstract 530]","volume":"114","author":"Mellqvist","year":"2009","journal-title":"Blood"},{"key":"2021122303313761100_B53","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma","volume":"28","author":"Ladetto","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B54","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.V116.21.42.42","article-title":"Bortezomib-thalidomide-dexamethasone compared with thalidomide-dexamethasone as induction and consolidation therapy before and after double autologous transplantation in newly diagnosed multiple myeloma: Results from a randomized phase 3 study [abstract 42]","volume":"116","author":"Cavo","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B56","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood.V116.21.861.861","article-title":"Molecular remission after bortezomib-thalidomide-dexamethasone compared with thalidomide-dexamethasone as consolidation therapy following double autologous transplantation for multiple myeloma: Results of a qualitative and quantitative analysis [abstract 861]","volume":"116","author":"Terragna","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B57","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","article-title":"Long-term follow-up of autotransplantation trials for multiple myeloma: Update of protocols conducted by the Intergroupe Francophone du My\u00e9lome, Southwest Oncology Group, and University of Arkansas for medical sciences","volume":"28","author":"Barlogie","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood.V116.21.39.39","article-title":"A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): The NCIC CTG MY.10 trial [abstract 39]","volume":"116","author":"Stewart","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood.V116.21.37.37","article-title":"Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract 37]","volume":"116","author":"McCarthy","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B60","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: Results of a randomized trial from the Turkish Myeloma Study Group","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur J Haematol"},{"key":"2021122303313761100_B61","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2010-05-285155","article-title":"Balancing act for elderly myeloma","volume":"116","author":"Palumbo","year":"2010","journal-title":"Blood"},{"issue":"suppl 2","key":"2021122303313761100_B62","first-page":"235","article-title":"MP versus MPT for previously untreated elderly patients with multiple myeloma: A meta analysis of survival of 1682 individual patient data from 6 randomized clinical trials [abstract 567]","volume":"95","author":"Waage","year":"2010","journal-title":"Haematologica"},{"key":"2021122303313761100_B63","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"key":"2021122303313761100_B64","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/blood.V116.21.1940.1940","article-title":"A multicenter, open label study of oral lenalidomide and prednisone (RP) followed by oral lenalidomide melphalan and prednisone (MPR) and oral lenalidomide maintenance in newly diagnosed elderly multiple myeloma patients [abstract 1940]","volume":"116","author":"Palumbo","year":"2010","journal-title":"Blood"},{"issue":"1 suppl","key":"2021122303313761100_B65","first-page":"512","article-title":"Similar benefit in patients aged \u226575 vs &lt;75 y with VMP in frontline MM and bortezomib in relapsed MM [abstract 084]","volume":"9","author":"Kropff","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"2021122303313761100_B66","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"2021122303313761100_B67","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-Melphalan-Prednisone-Thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B68","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1182\/blood.V116.21.312.312","article-title":"A phase 3 prospective randomized International study (MMY-3021) comparing subcutaneous and intravenous administration of bortezomib in patients with relapsed multiple myeloma [abstract 312]","volume":"116","author":"Moreau","year":"2010","journal-title":"Blood"},{"issue":"suppl 2","key":"2021122303313761100_B69","first-page":"149","article-title":"Outcome of elderly patients 70 years and older with newly diagnosed myeloma in the ECOG randomized trial of lenalidomide\/high-dose dexamethasone (RD) versus lenalidomide\/low-dose dexamethasone (Rd) [abstract 370]","volume":"95","author":"Jacobus","year":"2010","journal-title":"Haematologica"},{"key":"2021122303313761100_B70","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2008.07303.x","article-title":"The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma","volume":"143","author":"Niesvizky","year":"2008","journal-title":"Br J Haematol"},{"key":"2021122303313761100_B71","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B72","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","article-title":"Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"2021122303313761100_B73","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/leu.2010.175","article-title":"Treatment of patients with relapsed\/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: Prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies","volume":"24","author":"Dimopoulos","year":"2010","journal-title":"Leukemia"},{"key":"2021122303313761100_B74","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood.V116.21.1964.1964","article-title":"Efficacy of retreatment with immunomodulatory compounds in patients receiving initial therapy for newly diagnosed multiple myeloma [abstract 1964]","volume":"116","author":"Madan","year":"2010","journal-title":"Blood"},{"issue":"suppl 2","key":"2021122303313761100_B75","first-page":"152","article-title":"Efficacy and safety of retreatment with bortezomib in patients with multiple myeloma: Interim results from RETRIEVE, a prospective international phase 2 study [abstract 377]","volume":"95","author":"Petrucci","year":"2010","journal-title":"Haematologica"},{"key":"2021122303313761100_B76","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood.V114.22.2878.2878","article-title":"Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter International Myeloma Working Group study [abstract 2878]","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"2021122303313761100_B77","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","article-title":"VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III VISTA study","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B78","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1200\/JCO.2010.28.1238","article-title":"Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: Results of a phase II study","volume":"28","author":"Ludwig","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303313761100_B79","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.leukres.2010.04.024","article-title":"Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents","volume":"34","author":"Roussou","year":"2010","journal-title":"Leuk Res"},{"key":"2021122303313761100_B80","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/cncr.25139","article-title":"The efficacy and safety of lenalidomide plus dexamethasone in relapsed and\/or refractory multiple myeloma patients with impaired renal function","volume":"116","author":"Dimopoulos","year":"2010","journal-title":"Cancer"},{"key":"2021122303313761100_B81","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: The challenge continues","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122303313761100_B82","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"2021122303313761100_B83","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1182\/blood.V116.21.1935.1935","article-title":"Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: A phase III, randomized, multicenter trial based on lenalidomide-dexamethasone (Len-Dex) as induction therapy followed by maintenance therapy with Len alone vs so treatment [abstract 1935]","volume":"116","author":"Mateos","year":"2010","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2010-0386","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2010-0386","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/4\/388\/41853356\/oncolo_16_4_388.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/4\/388\/41853356\/oncolo_16_4_388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T05:02:56Z","timestamp":1640235776000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/4\/388\/6400791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,26]]},"references-count":83,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,3,26]]},"published-print":{"date-parts":[[2011,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2010-0386","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,4,1]]},"published":{"date-parts":[[2011,3,26]]}}}